---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-261204"
form_type: "8-K"
ticker: "HCA"
cik: "0000860730"
company_name: "HCA Healthcare, Inc."
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T15:34:36.196825+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HCA Healthcare Q3 revenue $16.21B, EPS $3.91; FY 2023 guidance revised; dividend $0.60

## Summary
- Revenue $16.213B (+8.3% YoY); net income $1.079B ($3.91 diluted EPS, flat vs $3.91 prior year).
- Adjusted EBITDA $2.88B, down from $2.902B; same-facility admissions +3.4%, equivalent admissions +4.1%.
- FY 2023 guidance revised: revenue $63.5-$64.5B, adjusted EBITDA $12.3-$12.6B, EPS $17.80-$18.50.
- Board declared $0.60/share dividend payable Dec 28 to holders of record Dec 14; Q3 buyback $1.14B, $1.685B remaining.
- CEO cited solid demand but Valesco physician staffing JV performed below expectations.

## SEC filing metadata
- accession: 0001193125-23-261204
- form_type: 8-K
- ticker: HCA
- cik: 0000860730
- company_name: HCA Healthcare, Inc.
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/860730/000119312523261204/0001193125-23-261204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/860730/000119312523261204/d551352d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-261204
- JSON: https://secwatch.observer/filing/0001193125-23-261204.json
- Plain text: https://secwatch.observer/filing/0001193125-23-261204.txt

## Key facts
- Earnings Releases
  HCA Healthcare, Inc. updated its year ending December 31, 2023 guidance (reaffirmed).
  - Period: year ending December 31, 2023
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The 2023 guidance ranges for the year have been revised from our second quarter release as follows: Previous 2023 Guidance Range as of July 27, 2023 2023 Guidance Range as of October 24, 2023 Revenues $63.25 to $64.75 billion $63.5 to $64.5 billion Net Income Attributable to HCA Healthcare, Inc. $4.900 to $5.255 billion $4.940 to $5.130 billion Adjusted EBITDA $12.3 to $12.8 billion $12.3 to $12.6 billion EPS (diluted) $17.70 to $18.90 per diluted share $17.80 to $18.50 per diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/860730/000119312523261204/0001193125-23-261204-index.htm
- Earnings Releases
  HCA Healthcare, Inc. reported third quarter ended September 30, 2023 results: revenue $16.213 billion, net income $1.079 billion, EPS $3.91 per diluted share.
  - Period: third quarter ended September 30, 2023
  - Revenue: $16.213 billion
  - Net income: $1.079 billion
  - EPS: $3.91 per diluted share
  - Result: reported results
  source text: results for the third quarter ended September 30, 2023. Key third quarter metrics (all percentage changes compare 3Q 2023 to 3Q 2022 unless otherwise noted): ● Revenues totaled $16.213 billion ● Net income attributable to HCA Healthcare, Inc. totaled $1.079 billion, or $3.91 per diluted share ● Adjusted EBITDA totaled $2.880 billion ● Cash flows from operating
  evidence_url: https://www.sec.gov/Archives/edgar/data/860730/000119312523261204/0001193125-23-261204-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.